Adlai Nortye Ltd (ANL) - News Archive

Showing 3 of 3 results.

Adlai Nortye Ltd Struggles to Keep Pace with the Market A Closer Look at Recent Events

In the increasingly competitive pharmaceutical industry, Adlai Nortye Ltd has been facing a challenging period as its shares trail behind the overall market performance. With a lackluster 15.22% year-to-date return, the...

Jun 25, 2024 • Major Pharmaceutical Preparations Industry Stocks on the Move Tuesday It Even June Adlai Nortye Ltd

Adlai Nortye Ltd. Presents Promising Data on AN0025 in Combination with Definitive Chemoradiotherapy for Unresectable Locally Advanced or Locally Recurrent Esophageal Cancer at ASCO 2024

Adlai Nortye Ltd. Presents Encouraging Data on AN0025 in Combination with Definitive Chemoradiotherapy for Esophageal CancerAdlai Nortye Ltd., a clinical-stage biotechnology company, is set to present promising prelimin...

May 24, 2024 • Major Pharmaceutical Preparations Industry Announcement ADLAI NORTYE

Adlai Nortye Launches Phase II ARTEMIS Trial to Enhance Rectal Cancer Treatment with Palupiprant'

Adlai Nortye Initiates Phase II Clinical Trial of Palupiprant for Locally Advanced Rectal Cancer Treatment Singapore, North Brunswick, NJ, and Hangzhou, China, May 22, 2024 Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-st...

May 22, 2024 • Major Pharmaceutical Preparations Industry Clinical Study ADLAI NORTYE